Japanese Dermatological Association Guidelines: Outlines of guidelines for cutaneous melanoma 2019-Reference-Cited by-同舟云学术

Japanese Dermatological Association Guidelines: Outlines of guidelines for cutaneous melanoma 2019

Published:2019-11-28 Issue:2 Volume:47 Page:89-103
ISSN:0385-2407
Container-title:The Journal of Dermatology
language:en
Short-container-title:J Dermatol

Author:

Nakamura Yasuhiro¹^ORCID,Asai Jun²^ORCID,Igaki Hiroshi³^ORCID,Inozume Takashi⁴^ORCID,Namikawa Kenjiro⁵^ORCID,Hayashi Ayato⁶^ORCID,Fukushima Satoshi⁷^ORCID,Fujimura Taku⁸^ORCID,Ito Takamichi⁹^ORCID,Imafuku Keisuke¹⁰^ORCID,Tanaka Ryota¹¹^ORCID,Teramoto Yukiko¹,Minagawa Akane¹²^ORCID,Miyagawa Takuya¹³^ORCID,Miyashita Azusa⁷^ORCID,Wada Makoto²^ORCID,Koga Hiroshi¹²^ORCID,Sugaya Makoto¹⁴^ORCID

Affiliation:

1. Department of Skin Oncology/Dermatology Saitama Medical University International Medical Center SaitamaJapan

2. Department of Dermatology Kyoto Prefectural University of Medicine KyotoJapan

3. Department of Radiation Oncology National Cancer Center Hospital TokyoJapan

4. Department of Dermatology University of Yamanashi KofuJapan

5. Department of Dermatologic Oncology National Cancer Center Hospital TokyoJapan

6. Department of Plastic and Reconstructive Surgery Juntendo University Urayasu Hospital UrayasuJapan

7. Department of Dermatology/Plastic and Reconstructive Surgery Kumamoto University KumamotoJapan

8. Department of Dermatology Tohoku University SendaiJapan

9. Department of Dermatology Graduate School of Medical Sciences Kyushu University FukuokaJapan

10. Department of Dermatology Hokkaido University SapporoJapan

11. Deparmtent of Dermatology Faculty of Medicine University of Tsukuba TsukubaJapan

12. Department of Dermatology Shinshu University MatsumotoJapan

13. Department of Dermatology University of Tokyo TokyoJapan

14. Department of Dermatology International University of Health and Welfare Narita Japan

Funder

Japanese Dermatological Association

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1346-8138.15151

Reference63 articles.

1. Adjuvant Dabrafenib plus Trametinib in Stage IIIBRAF-Mutated Melanoma

2. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

3. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

4. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

5. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Successful Multidisciplinary Treatment with Laparoscopic Hepatectomy and Adjuvant Therapy for Metachronous Solitary Hepatic Metastasis after Excision of a Primary Anorectal Malignant Melanoma: A Case Report;Current Oncology;2023-12-29

2. Current surgical management for melanoma;The Journal of Dermatology;2023-12-27

3. A real-world study on the safety profile of extended-interval dosing of immune checkpoint inhibitors for melanoma: a single-center analysis in Japan;Frontiers in Medicine;2023-12-07

4. Clinical practice guidelines for molecular tumor markers, 2nd edition review part 1;International Journal of Clinical Oncology;2023-11-29

5. Nail Apparatus Melanoma: Current Management and Future Perspectives;Journal of Clinical Medicine;2023-03-12